Aurinia Pharmaceuticals Inc - Common Shares (AUPH)

Aurinia Pharmaceuticals (NASDAQ:AUPH) shows strong growth metrics, including surging earnings, revenue, and cash flow, making it a candidate for investors following Louis Navellier’s strategy.

AUR200 targets both BAFF and APRIL, which are key immune system proteins. It is being developed for one large indication and one rare disease.

Aurinia Pharmaceuticals (AUPH) shows strong growth, earnings momentum, and improving margins, making it a candidate for investors following Louis Navellier’s strategy.

U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket.

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

The biotech's premium valuation doesn't seem to be sitting well with investors.

Aurinia Pharmaceuticals (AUPH) meets Louis Navellier’s growth criteria with strong earnings surprises, accelerating revenue, and improving margins. A solid pick for growth-focused investors.

Aurinia posts Q1 profit and 25% LUPKYNIS sales growth, reports $62.47 million revenue, and reaffirms full-year guidance.

The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.

Should you consider AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) for high growth investing? A fundamental and technical analysis of (NASDAQ:AUPH).

Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.

Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%.

AUPH stock results show that Aurinia Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Aurinia Pharmaceuticals Q4 2023 results: EPS loss $(0.19), sales $45.1 million. AUR200 development halted. Strategic review concludes. $150 million share buyback initiated.

Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings.

Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) shares are trending on social media Friday. The company provided its preliminary, unaudited fourth-quarter and fiscal year 2023 financial results. What To Know:

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week.

On CNBC’s "Mad Money Lightning Round," Jim Cramer said BP (NYSE: BP) is "not great, not bad." He added, "This whole group is going through a real re-evaluation.

The biotech's board is exploring strategic alternatives to boost shareholder value.

Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms.